1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium

• ChemBase ID: 1171
• Molecular Formular: C34H57N2O4+
• Molecular Mass: 557.82738
• Monoisotopic Mass: 557.43183331
• SMILES: [C@@]12([C@H]([C@H]3[C@H](CC2)[C@@]2([C@@H](CC3)C[C@@H]([C@H](C2)N2CCCCC2)OC(=O)C)C)C[C@@H]([C@@H]1OC(=O)C)[N+]1(CCCCC1)C)C
• Canonical SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N1CCCCC1)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)[N+]1(C)CCCCC1)C
• InChI: InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
• InChIKey: BGSZAXLLHYERSY-XQIGCQGXSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
• IUPAC Traditional name: vecuronium
• Synonyms: Vecuronium

Database IDs

• CAS Number: 50700-72-6
• PubChem SID: 160964634; 46507656
• PubChem CID: 39765

CALCULATED PROPERTIES

JChem

• H Acceptors: 3
• H Donor: 0
• LogD (pH = 5.5): -2.5210478
• LogD (pH = 7.4): -1.3351427
• Log P: 0.8920891
• Molar Refractivity: 169.3084 cm^3
• Polarizability: 63.49572 Å^3
• Polar Surface Area: 55.84 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 2.07
• LOG S: -7.5
• Solubility (Water): 1.86e-05 g/l

DETAILS

DrugBank - DB01339

• Drug Groups: approved
• Description: Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]
• Indication: Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
• Pharmacology: Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
• Biotransformation: 100%
• Half Life: 51–80 minutes
• Elimination: Fecal (40-75%) and renal (30% as unchanged drug and metabolites)
• External Links: Wikipedia; Drugs.com